Online citations, reference lists, and bibliographies.
← Back to Search

Structure-based Design Of Peptides With High Affinity And Specificity To HER2 Positive Tumors

Lingling Geng, Zihua Wang, X. Yang, D. Li, Wenxi Lian, Zhichu Xiang, Weizhi Wang, Xiangli Bu, W. Lai, Z. Hu, Qiaojun Fang
Published 2015 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
To identify peptides with high affinity and specificity against human epidermal growth factor receptor 2 (HER2), a series of peptides were designed based on the structure of HER2 and its Z(HER2:342) affibody. By using a combination protocol of molecular dynamics modeling, MM/GBSA binding free energy calculations, and binding free energy decomposition analysis, two novel peptides with 27 residues, pep27 and pep27-24M, were successfully obtained. Immunocytochemistry and flow cytometry analysis verified that both peptides can specifically bind to the extracellular domain of HER2 protein at cellular level. The Surface Plasmon Resonance imaging (SPRi) analysis showed that dissociation constants (KD) of these two peptides were around 300 nmol/L. Furthermore, fluorescence imaging of peptides against nude mice xenografted with SKBR3 cells indicated that both peptides have strong affinity and high specificity to HER2 positive tumors.
This paper references
10.1007/s00259-005-0012-3
Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice
Ann-Charlott Steffen (2005)
10.1200/JCO.2006.07.0250
Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer.
Z. Gabos (2006)
10.3390/molecules190915196
Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer
Richard L. Schroeder (2014)
10.1021/JM0609162
Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance.
T. Hou (2007)
10.1093/PROTEIN/1.2.107
A synthetic IgG-binding domain based on staphylococcal protein A.
B. Nilsson (1987)
10.1016/j.jmb.2007.12.054
Characterization of domain-peptide interaction interface: a case study on the amphiphysin-1 SH3 domain.
T. Hou (2008)
tein - peptide arrays for detection of specific anti - hepatitis D virus ( HDV ) genotype 1 , 6 , and 8 antibodies among HDV - infected patients by surface plasmon resonance imaging
W Wang (2015)
10.2967/jnumed.109.073239
Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules
R. Baum (2010)
10.3892/ol.2014.2250
Cathepsin D serum and urine concentration in superficial and invasive transitional bladder cancer as determined by surface plasmon resonance imaging
E. Gorodkiewicz (2014)
10.1093/PROTEIN/GZH053
Selection and characterization of HER2/neu-binding affibody ligands.
M. Wikman (2004)
10.1016/J.CCR.2006.10.008
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
R. Neve (2006)
10.4137/BCBCR.S0
The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines
Kristina Subik (2010)
10.1126/SCIENCE.3798106
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
10.1039/c4cp03179b
Assessing the performance of MM/PBSA and MM/GBSA methods. 5. Improved docking performance using high solute dielectric constant MM/GBSA and MM/PBSA rescoring.
Huiyong Sun (2014)
10.1038/35052073
Untangling the ErbB signalling network
Y. Yarden (2001)
10.1016/J.CANLET.2005.01.041
Herceptin: mechanisms of action and resistance.
R. Nahta (2006)
10.1073/PNAS.89.10.4285
Humanization of an anti-p185HER2 antibody for human cancer therapy.
P. Carter (1992)
10.1002/minf.201100135
Free Energy Calculations by the Molecular Mechanics Poisson−Boltzmann Surface Area Method
Nadine Homeyer (2012)
10.1016/j.bbrc.2008.10.027
Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line.
L. Ekerljung (2008)
10.1021/ac5023056
Label-Free Quantitative Detection of Tumor-Derived Exosomes through Surface Plasmon Resonance Imaging
Ling Zhu (2014)
10.1016/S0959-8049(01)00230-1
The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.
Y. Yarden (2001)
10.1007/s10822-012-9617-3
Computational insights into the selectivity mechanism of APP-IP over matrix metalloproteinases
Lingling Geng (2012)
10.1002/jcc.20290
The Amber biomolecular simulation programs
D. A. Case (2005)
10.1063/1.464397
Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems
T. Darden (1993)
10.1074/mcp.M800450-MCP200
Characterization of Domain-Peptide Interaction Interface
T. Hou (2009)
10.1002/1097-0282(2000)56:4<275::AID-BIP10024>3.0.CO;2-E
Theory and applications of the generalized born solvation model in macromolecular simulations
V. Tsui (2000)
10.1073/pnas.1005025107
Structural basis for high-affinity HER2 receptor binding by an engineered protein
C. Eigenbrot (2010)
10.1158/0008-5472.CAN-05-3521
Tumor imaging using a picomolar affinity HER2 binding affibody molecule.
A. Orlová (2006)
10.1089/CBR.2005.20.239
In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics.
Ann-Charlott Steffen (2005)
meric HER 2 - specific affibody molecules inhibit proliferation of the SKBR - 3 breast cancer cell line
RP Baum (2008)
10.2174/157340906778226454
Recent advances in free energy calculations with a combination of molecular mechanics and continuum models
J. Wang (2006)
10.1002/prot.20033
Exploring protein native states and large‐scale conformational changes with a modified generalized born model
A. Onufriev (2004)
10.1016/j.talanta.2014.12.012
Label-free detection microarray for novel peptide ligands screening base on MS-SPRi combination.
Weizhi Wang (2015)
10.1128/JCM.03002-14
Protein-Peptide Arrays for Detection of Specific Anti-Hepatitis D Virus (HDV) Genotype 1, 6, and 8 Antibodies among HDV-Infected Patients by Surface Plasmon Resonance Imaging
M. Villiers (2015)
10.1200/JCO.1993.11.10.1936
Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.
R. Seshadri (1993)
10.1093/bioinformatics/btm404
Clustal W and Clustal X version 2.0
Mark A. Larkin (2007)
10.1002/jcc.10349
A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculations
Y. Duan (2003)
10.1021/ci100275a
Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations
T. Hou (2011)
10.1021/ci300526u
Unraveling the Allosteric Inhibition Mechanism of PTP1B by Free Energy Calculation Based on Umbrella Sampling
Wei Cui (2013)
10.1021/AR000033J
Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models.
P. Kollman (2000)
10.1021/ac503454z
Rapid screening of peptide probes through in situ single-bead sequencing microarray.
Weizhi Wang (2014)
10.4142/jvs.2013.14.4.473
Distribution and accumulation of Cy5.5-labeled thermally cross-linked superparamagnetic iron oxide nanoparticles in the tissues of ICR mice
J. J. Hue (2013)
10.1158/1078-0432.CCR-07-4076
Affibody Molecules for In vivo Characterization of HER2-Positive Tumors by Near-Infrared Imaging
S. B. Lee (2008)
10.1002/(SICI)1096-987X(19990130)20:2%3C217::AID-JCC4%3E3.0.CO;2-A
Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO)
J. Weiser (1999)
10.1016/S0022-2836(03)00610-7
Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes.
H. Gohlke (2003)
10.1093/nar/28.1.235
The Protein Data Bank
H. Berman (2000)
10.1016/S1097-2765(03)00350-2
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.
A. Burgess (2003)
10.1158/0008-5472.CAN-06-1630
Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
V. Tolmachev (2007)
Particle mesh Ewald: An N [center-dot] log(N) method for Ewald sums in large systems
T Darden (1993)
10.1016/0021-9991(77)90098-5
Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes
Jean-Paul Ryckaert (1977)
10.1110/ps.03351704
Validation of helical tilt angles in the solution NMR structure of the Z domain of Staphylococcal protein A by combined analysis of residual dipolar coupling and NOE data
D. Zheng (2004)
The PyMOL Molecular Graphics System
W. Delano (2002)
10.1063/1.445869
Comparison of simple potential functions for simulating liquid water
W. Jorgensen (1983)
10.1016/S0014-4827(02)00099-X
The ErbB receptors and their role in cancer progression.
T. Holbro (2003)
10.1016/S1535-6108(04)00083-2
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.
M. C. Franklin (2004)
10.1126/SCIENCE.2470152
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
D. Slamon (1989)
Theory and applications of the generalized Born solvation model in macromolecular simulations. Biopolymers
V Tsui (2000)
10.1038/nature01392
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Hyun-Soo Cho (2003)
10.1007/s11912-013-0359-8
New HER2-Positive Targeting Agents in Clinical Practice
S. Tolaney (2014)



This paper is referenced by
10.2967/jnumed.116.183863
SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe 99mTc-HYNIC-H6F in Breast Cancer Mouse Models
L. Li (2017)
10.1039/d0nr01892a
Drug-internalized bacterial swimmers for magnetically manipulable tumor-targeted drug delivery.
Zhichu Xiang (2020)
10.1016/j.lfs.2019.116870
Recent developments in peptide-based SPECT radiopharmaceuticals for breast tumor targeting.
S. Ahmadpour (2019)
10.1101/2019.12.18.878504
Systematic development of peptide inhibitors targeting the CXCL12/HMGB1 interaction
Jacopo Sgrignani (2020)
10.1039/C9TB00433E
Improved tumor targeting and penetration by a dual-functional poly(amidoamine) dendrimer for the therapy of triple-negative breast cancer
C. Liu (2019)
10.3390/pharmaceutics11030119
Computational Approaches in Theranostics: Mining and Predicting Cancer Data
Tânia Cova (2019)
10.1371/journal.pcbi.1005441
Peptide probes derived from pertuzumab by molecular dynamics modeling for HER2 positive tumor imaging
X. Yang (2017)
10.7150/thno.14302
HER2 Targeting Peptides Screening and Applications in Tumor Imaging and Drug Delivery
Lingling Geng (2016)
10.3390/molecules25040808
Targeting Tumors Using Peptides
P. Scodeller (2020)
10.1016/j.biomaterials.2017.11.024
Structure-based design for binding peptides in anti-cancer therapy.
S. Wang (2018)
10.7150/ntno.38954
Enhanced blood-brain-barrier penetrability and tumor-targeting efficiency by peptide-functionalized poly(amidoamine) dendrimer for the therapy of gliomas
Changliang Liu (2019)
10.1039/C6RA13657E
Biomimetic fabrication of biotinylated peptide nanostructures upon diatom scaffold; a plausible model for sustainable energy
V. Kumar (2016)
10.3390/biom10020183
Structure–Activity Relationship of HER2 Receptor Targeting Peptide and Its Derivatives in Targeted Tumor Therapy
Beáta Biri-Kovács (2020)
10.1016/j.tranon.2017.04.003
Preparation and Identification of HER2 Radioactive Ligands and Imaging Study of Breast Cancer-Bearing Nude Mice1
M. Zhang (2017)
10.1016/j.csbj.2019.07.010
Applications of Molecular Dynamics Simulation in Structure Prediction of Peptides and Proteins
H. Geng (2019)
10.1016/j.nano.2016.07.013
HER2-positive breast cancer targeting and treatment by a peptide-conjugated mini nanodrug.
Hui Ding (2017)
10.1186/s12890-018-0760-z
Real-time molecular optical micro-imaging of EGFR mutations using a fluorescent erlotinib based tracer
M. Patout (2019)
10.1038/s41598-019-40562-1
Rational Identification of a Colorectal Cancer Targeting Peptide through Phage Display
D. Ferreira (2019)
10.3390/biom9110706
Dynamical Rearrangement of Human Epidermal Growth Factor Receptor 2 upon Antibody Binding: Effects on the Dimerization
Pedro R. Magalhães (2019)
10.3390/molecules25071756
How Computational Chemistry and Drug Delivery Techniques Can Support the Development of New Anticancer Drugs
Mariangela Garofalo (2020)
10.1016/j.biomaterials.2016.11.022
Tumor detection using magnetosome nanoparticles functionalized with a newly screened EGFR/HER2 targeting peptide.
Zhichu Xiang (2017)
10.1021/acs.bioconjchem.5b00565
Design and Synthesis of Near-Infrared Peptide for in Vivo Molecular Imaging of HER2.
B. Joshi (2016)
Semantic Scholar Logo Some data provided by SemanticScholar